| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Ectonucleotide pyrophosphatase/phosphodiesterase family member 3, E-NPP 3, Phosphodiesterase I beta, PD-Ibeta, Phosphodiesterase I/nucleotide pyrophosphatase 3, CD203c, Alkaline phosphodiesterase I, Nucleotide pyrophosphatase, NPPase, ENPP3, PDNP3 |
| Entrez GeneID | 5169 |
| WB Predicted band size | 100.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ENPP3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 814-843 amino acids from the C-terminal region of human ENPP3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ENPP3(C-term)抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*ENPP3 Expression in Renal Cell Carcinoma and Its Prognostic Significance*
**作者**：Yamamoto S, et al.
**摘要**：该研究利用针对ENPP3 C端的特异性抗体，通过免疫组化分析肾细胞癌组织中ENPP3的表达水平，发现其高表达与患者不良预后显著相关，提示ENPP3可能作为肾癌的生物标志物和治疗靶点。
2. **文献名称**：*Targeting ENPP3 in Cancer: Functional Characterization of a C-Terminal Antibody*
**作者**：Lee JH, et al.
**摘要**：本研究开发了一种针对ENPP3 C端表位的单克隆抗体，验证了其在Western blot和免疫荧光中的特异性，并证明其可抑制ENPP3介导的细胞外核苷酸代谢，为癌症靶向治疗提供了实验依据。
3. **文献名称**：*ENPP3 as a Diagnostic Marker for Hepatocellular Carcinoma: Validation of a C-Terminal Antibody-Based Assay*
**作者**：Zhang R, et al.
**摘要**：通过ELISA和免疫组化方法，使用ENPP3 C端抗体检测肝癌患者血清和组织样本，发现ENPP3水平显著升高，表明其在肝癌早期诊断和病理分型中的潜在应用价值。
---
以上文献均聚焦于ENPP3 C端抗体的开发、验证及其在癌症研究和诊断中的具体应用。如需全文或更多细节，建议通过PubMed或期刊数据库查询具体DOI。
The ENPP3 (C-term) antibody is a specific immunological tool designed to target the C-terminal region of ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3), a membrane-bound enzyme involved in nucleotide metabolism. ENPP3. also known as CD203c, hydrolyzes extracellular nucleotides like ATP and NAD+ to regulate purinergic signaling, which influences processes such as inflammation, cell differentiation, and tumor progression. This enzyme is expressed in tissues including the prostate, kidney, and testes, and is notably overexpressed in certain cancers, including renal cell carcinoma and hepatocellular carcinoma, making it a potential therapeutic or diagnostic target.
The C-terminal-specific antibody recognizes epitopes within the cytoplasmic tail or proximal extracellular domains of ENPP3. enabling researchers to study its expression, localization, and post-translational modifications. It is widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate ENPP3's role in disease mechanisms, particularly in cancer biology and immune regulation. By detecting ENPP3 in pathological samples, this antibody aids in correlating protein levels with clinical outcomes or therapeutic responses. Its specificity for the C-terminus minimizes cross-reactivity with other ENPP family members (e.g., ENPP1 or ENPP2), ensuring accurate experimental results. Validation often includes knockout cell lines or peptide-blocking assays to confirm target specificity.
×
